Greenland Mines (GRML) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Greenland Mines (GRML) over the past year, losing 49.5% versus a loss of 87.1%. OKYO Pharma is the larger company by market cap ($56.2 million vs $44.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRML | OKYO |
|---|---|---|
| Share price | $2.99 | $1.07 |
| Market cap | $44.31M | $56.15M |
| 1-day change | +2.75% | -7.76% |
| YTD return | -79.31% | -48.31% |
| 1-year return | -87.08% | -49.53% |
| EPS (TTM) | $-9.74 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-10.55M | $-4.71M |
| 52-week high | $37.00 | $3.20 |
| 52-week low | $2.75 | $1.00 |
| Distance from 52-week high | -91.92% | -66.56% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +3578.93% | +678.50% |
| Average volume | 8.93M | 143.41K |
| Shares outstanding | 14.82M | 52.48M |
| Employees | 5 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKYO has outperformed GRML by 37.6 percentage points over the past year.
About Greenland Mines
GRML stock →Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
GRML vs OKYO FAQ
Which is bigger, Greenland Mines or OKYO Pharma?
OKYO Pharma (OKYO) is larger, with a market capitalization of $56.15M compared with $44.31M for Greenland Mines (GRML).
Which stock has performed better over the past year, GRML or OKYO?
OKYO returned -49.53% over the past 12 months, compared with -87.08% for GRML (price return, excluding dividends). Past performance does not predict future results.
Are Greenland Mines and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.